O	0	3	Ten
O	3	4	-
O	4	8	year
O	9	15	follow
O	15	16	-
O	16	18	up
O	19	21	of
O	22	23	a
O	24	34	randomized
O	35	45	controlled
O	46	51	trial
O	52	54	of
B-intervention	55	63	adjuvant
I-intervention	64	74	clodronate
O	75	84	treatment
O	85	87	in
O	88	92	node
O	92	93	-
O	93	101	positive
O	102	108	breast
O	109	115	cancer
O	116	124	patients
O	124	125	.

O	126	129	Ten
O	129	130	-
O	130	134	year
O	135	141	follow
O	141	142	-
O	142	144	up
O	145	152	results
O	153	156	are
O	157	166	presented
O	167	169	of
O	170	172	an
O	173	181	adjuvant
O	182	192	clodronate
O	193	198	trial
O	199	201	in
O	202	210	patients
O	211	215	with
O	216	223	primary
O	224	230	breast
O	231	237	cancer
O	237	238	.

O	239	246	Between
O	247	251	1990
O	252	255	and
O	256	260	1993
O	260	261	,
B-total-participants	262	265	299
B-eligibility	266	271	women
I-eligibility	272	276	with
I-eligibility	277	284	primary
I-eligibility	285	289	node
I-eligibility	290	298	positive
I-eligibility	299	305	breast
I-eligibility	306	312	cancer
O	313	317	were
O	318	328	randomized
O	329	331	to
O	332	336	oral
O	337	347	clodronate
O	348	352	1600
O	353	355	mg
O	356	361	daily
O	362	363	(
B-intervention-participants	363	366	149
O	366	367	)
O	368	370	or
B-control	371	379	controls
O	380	381	(
B-control-participants	381	384	150
O	384	385	)
O	386	389	for
O	390	391	3
O	392	397	years
O	397	398	.

O	399	402	All
O	403	411	patients
O	412	420	received
O	421	429	adjuvant
O	430	435	chemo
O	435	436	-
O	437	439	or
O	440	449	endocrine
O	450	457	therapy
O	457	458	.

O	459	465	Within
O	466	468	10
O	469	474	years
B-outcome	475	479	bone
I-outcome	480	490	metastases
O	491	495	were
O	496	504	detected
O	505	507	at
O	508	511	the
O	512	516	same
O	517	526	frequency
O	527	529	in
O	530	533	the
O	534	544	clodronate
O	545	548	and
O	549	556	control
O	557	563	groups
O	563	564	:
B-iv-bin-abs	565	567	44
O	568	569	(
B-iv-bin-percent	569	571	32
I-iv-bin-percent	571	572	%
O	572	573	)
O	574	576	vs
O	576	577	.
B-cv-bin-abs	578	580	42
O	581	582	(
B-cv-bin-percent	582	584	29
I-cv-bin-percent	584	585	%
O	585	586	)
O	586	587	,
O	588	600	respectively
O	600	601	,
O	602	603	(
O	603	604	p
O	604	605	=
O	605	606	0
O	606	607	.
O	607	609	35
O	609	610	)
O	610	611	.

O	612	615	The
B-outcome	616	625	frequency
I-outcome	626	628	of
I-outcome	629	632	non
I-outcome	632	633	-
I-outcome	633	641	skeletal
I-outcome	642	653	recurrences
O	654	655	(
O	655	663	visceral
O	664	667	and
O	668	673	local
O	673	674	)
O	675	678	was
O	679	692	significantly
O	693	699	higher
O	700	702	in
O	703	706	the
O	707	717	clodronate
O	718	723	group
B-iv-bin-abs	724	726	69
O	727	728	(
B-iv-bin-percent	728	730	50
I-iv-bin-percent	730	731	%
O	731	732	)
O	733	735	as
O	736	744	compared
O	745	749	with
O	750	753	the
O	754	762	controls
B-cv-bin-abs	763	765	51
O	766	767	(
B-cv-bin-percent	767	769	36
I-cv-bin-percent	769	770	%
O	770	771	)
O	772	773	(
O	773	774	p
O	774	775	=
O	775	776	0
O	776	777	.
O	777	780	005
O	780	781	)
O	781	782	.

B-outcome	783	786	Ten
I-outcome	786	787	-
I-outcome	787	791	year
I-outcome	792	799	disease
I-outcome	799	800	-
I-outcome	800	804	free
I-outcome	805	813	survival
I-outcome	814	815	(
I-outcome	815	818	DFS
I-outcome	818	819	)
O	820	828	remained
O	829	842	significantly
O	843	848	lower
O	849	851	in
O	852	855	the
O	856	866	clodronate
O	867	872	group
O	873	874	(
B-iv-bin-percent	874	876	45
I-iv-bin-percent	876	877	%
O	878	880	vs
O	880	881	.
B-cv-bin-percent	882	884	58
I-cv-bin-percent	884	885	%
O	885	886	,
O	887	888	p
O	888	889	=
O	889	890	0
O	890	891	.
O	891	893	01
O	893	894	,
O	895	907	respectively
O	907	908	)
O	908	909	.

O	910	914	This
O	915	918	was
O	919	929	especially
O	930	934	seen
O	935	937	in
B-outcome	938	947	oestrogen
I-outcome	948	956	receptor
I-outcome	957	965	negative
I-outcome	966	974	patients
O	975	976	(
B-iv-bin-percent	976	978	25
I-iv-bin-percent	978	979	%
O	980	982	vs
O	982	983	.
B-cv-bin-percent	984	986	58
I-cv-bin-percent	986	987	%
O	987	988	,
O	989	990	p
O	990	991	=
O	991	992	0
O	992	993	.
O	993	996	004
O	996	997	,
O	998	1010	respectively
O	1010	1011	)
O	1011	1012	.

O	1013	1015	No
O	1016	1027	significant
B-outcome	1028	1035	overall
I-outcome	1036	1044	survival
O	1045	1055	difference
O	1056	1059	was
O	1060	1065	found
O	1066	1073	between
O	1074	1077	the
O	1078	1084	groups
O	1084	1085	.

O	1086	1088	As
O	1089	1099	previously
O	1100	1108	reported
O	1109	1110	3
O	1110	1111	-
O	1111	1115	year
O	1116	1124	adjuvant
O	1125	1135	clodronate
O	1136	1145	treatment
O	1146	1149	did
O	1150	1153	not
O	1154	1161	prevent
O	1162	1165	the
O	1166	1177	development
O	1178	1180	of
O	1181	1185	bone
O	1186	1196	metastases
O	1197	1199	in
O	1200	1204	node
O	1204	1205	-
O	1205	1213	positive
O	1214	1220	breast
O	1221	1227	cancer
O	1228	1236	patients
O	1236	1237	.

O	1238	1239	A
O	1240	1248	negative
O	1249	1255	effect
O	1256	1258	of
O	1259	1269	clodronate
O	1270	1272	on
O	1273	1276	DFS
O	1277	1279	by
O	1280	1290	increasing
O	1291	1294	the
O	1295	1306	development
O	1307	1309	of
O	1310	1318	visceral
O	1319	1329	metastases
O	1330	1333	was
O	1334	1339	still
O	1340	1344	seen
O	1345	1347	at
O	1348	1350	10
O	1351	1356	years
O	1356	1357	,
O	1358	1361	but
O	1362	1366	this
O	1367	1370	did
O	1371	1374	not
O	1375	1388	significantly
O	1389	1399	compromise
O	1400	1407	overall
O	1408	1416	survival
O	1416	1417	.
